MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
95.35
+3.10
+3.36%
After Hours: 96.00 +0.65 +0.68% 19:39 12/12 EST
OPEN
92.72
PREV CLOSE
92.25
HIGH
95.39
LOW
91.70
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
95.39
52 WEEK LOW
33.70
MARKET CAP
5.96B
P/E (TTM)
151.04
1D
5D
1M
3M
1Y
5Y
1D
Protagonist Therapeutics Price Target Raised to $115.00/Share From $98.00 by Citigroup
Dow Jones · 5d ago
Protagonist Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 5d ago
Citigroup Maintains Buy on Protagonist Therapeutics, Raises Price Target to $115
Benzinga · 5d ago
Promising Clinical Data and Strategic Collaborations Drive Buy Rating for Protagonist Therapeutics
TipRanks · 5d ago
Protagonist Therapeutics price target raised to $115 from $98 at Citi
TipRanks · 5d ago
PROTAGONIST THERAPEUTICS INC <PTGX.O>: CITIGROUP RAISES TARGET PRICE TO $115 FROM $98
Reuters · 5d ago
Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera
Reuters · 5d ago
Weekly Report: what happened at PTGX last week (1201-1205)?
Weekly Report · 5d ago
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.